The Canonsburg, Pa.-based drugmaker recalled four lots of amiodarone HCl injection, which treats heart rhythm issues, and tranexamic acid injection, which promotes blood clotting.
Both medications are administered by healthcare professionals in hospital or clinic settings. Mylan is notifying its wholesalers and hospital pharmacies of the recall by letter.
The drugmaker has not received any reports of adverse events.
More articles on pharmacy:
FDA extends remdesivir’s emergency use authorization to all hospitalized COVID-19 patients
Walgreens names former Rite Aid CEO as its new president
78% of Americans think vaccine approval process is too politics-driven
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
